PDA frequently exhibits activating mutations in the KRAS gene, which drive tumor initiation and growth, and inactivating mutations in tumor suppressor genes such as CDKN2A/p16, TP53, and SMAD4, which contribute to aggressive tumor development [16]. The gene discussed is CDKN2A; the disease is neoplasm.